Vorinostat 99% Pharmaceutical CS-1949 White Powder CAS 149647-78-9 Vorinostat
COA TDS 14 Inquiries
149647-78-9
Pharmaceutical Grade
99%
shenzhen
HS
25kg drum
2026-09-20
Ivermectin,Active pharmaceutical ingredients,Cosmetics material,Chemical intermediate,Nootropic,Food additive
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceIt is the first HDAC inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma (CTCL) with significant skin involvement that is still progressing, resistant or relapsing after two systemic regimens. On October 6, 2006, the US Food and Drug Administration (FDA) have approved vorinostat capsules (vorinostat) for the treatment of skin cancer drugs. The drug is the first novel type of anti-cancer drugs of histone deacetylase inhibitor devel.
Solid
Vorinostat is a dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). It has a role as an EC 3.5.1.98 (histone deacetylase) inhibitor, an apoptosis inducer and an antineoplastic agent. It is a hydroxamic acid and a dicarboxylic acid diamide. It derives from a suberic acid, a hydroxylamine and an aniline.|Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned using combinations of vorinostat with other drugs.|Vorinostat is a Histone Deacetylase Inhibitor. The mechanism of action of vorinostat is as a Histone Deacetylase Inhibitor.|Vorinostat is an oral histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous T cell lymphoma. Vorinostat is associated with modest rate of minor serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent liver injury.|Vorinostat is a synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.|A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.CertificatesBasic Info-
Product Name:
Vorinostat
Other Name:Octanediamide,N1-hydroxy-N8-phenyl-;Octanediamide,N-hydroxy-N′-phenyl-;N1-Hydroxy-N8-phenyloctanediamide;SAHA;Suberoylanilide hydroxamic acid;Vorinostat;Zolinza;N-Hydroxy-N′-phenyloctanediamide;Suberoyl anilide bishydroxamide;WT 171
CAS No.:149647-78-9
Molecular Formula:C14H20N2O3
InChIKeys:InChIKey=WAEXFXRVDQXREF-UHFFFAOYSA-N
Molecular Weight:264.32
Exact Mass:264.32
EC Number:1308068-626-2
UNII:58IFB293JI
NSC Number:759852|748799|701852
DSSTox ID:DTXSID6041133
NCI Thesaurus Code:C1796
Color/Form:White to light orange powder|White solid
ATC Code:L - Antineoplastic and immunomodulating agents
HScode:29280000
Categories:
Characteristics-
PSA:
78.4
XLogP3:1.9
Appearance:white to tan
Density:1.2
Melting Point:159-160.5 °C
Refractive Index:1.567
Water Solubility:DMSO: ≥15mg/mL
Storage Conditions:-20°C Freezer
Vapor Pressure:2.6X10-13 mm Hg at 25 deg C (est)
PH:pH = 6.6 (saturated water solution)
PKA:9.2None
Henrys Law Constant:Henry's Law constant = 1.23X10-14 atm-cu m/mol at 25 °C (est)
Dissociation Constants:9.2|pKa = 9.2
Experimental Properties:... no chiral centers and is non-hygroscopic|Hydroxyl radical reaction rate constant = 3.147X10-11 cu cm/molec-sec at 25 °C (est)
Hazard IdentificationClassification of the substance or mixture
Germ cell mutagenicity, Category 2
Reproductive toxicity, Category 1A
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H341 Suspected of causing genetic defects
H360 May damage fertility or the unborn child
Precautionary statement(s) Prevention P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Ivermectin,Active pharmaceutical ingredients,Cosmetics material,Chemical intermediate,Nootropic,Food additive
-
Location:
6 floor Baoyilongji Building B Weiyang Area, Fengcheng 8 Road, Xi'an city, Shaanxi, 710000, China
-
Payment Terms:
L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2017
-
Certifications:
ISO,ISO
-
-
Inquiry History14 Inquiries
Country Product Purchase Quantity Date Posted 
Jordan
Vorinostat
1000 MG Jan 30, 2026 
Saudi Arabia
Vorinostat
5 KG Jul 6, 2025 
Italy
Vorinostat
10 G Aug 5, 2026 
Belgium
vorinostat
2 G Apr 16, 2026 
Brazil
Vorinostat
5 Feb 22, 2025 
Cyprus
Vorinostat
100 G Nov 26, 2024 
Spain
Vorinostat
10 G Aug 20, 2026 
Australia
Vorinostat
10 G Aug 9, 2026 
United States
Vorinostat
3 G Aug 6, 2025
United States
Vorinostat
50 G Jul 6, 2025 
United Kingdom
Vorinostat
5 G Jul 6, 2025
United States
Vorinostat
2 KG Jun 28, 2025 
Austria
Vorinostat
2000 MG Jun 7, 2025 
Russia
Vorinostat
100 G Mar 3, 2025 Post an enquiry for this product
